Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07566390 | A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity | PHASE1 | RECRUITING | 48 | — | — | May 1, 2026 | Nov 26, 2026 | Jun 4, 2026 | 1 | United States |
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 1 subcutaneously. |
| Cohort 2 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 2 subcutaneously. |
| Cohort 3 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 3 subcutaneously. |
| Cohort 4 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 4 subcutaneously. |
| Cohort 5 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 5 subcutaneously. |
| Cohort 6 NNC0113-5840 | EXPERIMENTAL | Participants will be randomized to receive NNC0113-5840 single dose level 6 subcutaneously. |
| Placebo matching NNC0113-5840 | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC0113-5840 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0113-5840 | DRUG | NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin. |
| Placebo | DRUG | Placebo matched to NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin. |
Inclusion Criteria: 1. Male or female 2. Age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the ...